Can an oral Anti-Inflammatory drug tame a painful skin condition?
NCT ID NCT07727889
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial is investigating whether upadacitinib, an oral drug that blocks inflammation, can help people with moderate-to-severe hidradenitis suppurativa—a chronic skin disease causing painful lumps, abscesses, and scarring. Fifty adults will take upadacitinib daily for 24 weeks, with the option to increase the dose based on response. Researchers will track whether the drug reduces skin lesions and improves quality of life, while also monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- upadacitinib, an oral drug that targets inflammation
- What this could lead to
- If it works, this could offer a new treatment option for people with moderate-to-severe hidradenitis suppurativa who haven't responded to other therapies.
- What could go wrong
- This is a small, early-phase trial with no placebo group, so results may not be definitive. Upadacitinib also carries risks like infections and blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (ACNE INVERSA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No. 1 Shuai Fu Yuan, Dongcheng District, Beijing
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.